Home>Topics>Industry>Biotechnology Industry

Biotechnology Industry

  1. All
  2. Stock Reports
  1. New Morningstar Analyst Report for MannKind Corp

    Stock Reports

    Wed, 13 Aug 2014

    Despite Afrezza's approval and partnership with Sanofi, the product could flop on the market. Exubera was removed from the market after it was deemed a commercial failure thanks to its hefty price tag and bulky design.Beyond Afrezza, MannKind has only a few early-stage products in its pipeline,

  2. New Morningstar Analyst Report for Cubist Pharmaceuticals Inc

    Stock Reports

    Wed, 13 Aug 2014

    Optimer and Trius acquisitions reduce Cubist's uncertainty post-Cubicin patent expiration.

  3. New Morningstar Analyst Report for Dendreon Corp

    Stock Reports

    Tue, 12 Aug 2014

    Dendreon’s high debt load and ongoing losses make the company’s long-term viability uncertain.Dendreon's limited sales and distribution know-how may hamper Provenge's uptake, and its lack of manufacturing experience could expose the firm to damaging supply issues.The treatment paradigm for prostate

  4. New Morningstar Analyst Report for Lexicon Pharmaceuticals Inc

    Stock Reports

    Fri, 8 Aug 2014

    Lexicon could move its diabetes drug forward without a partner, but costs and risks are high.

  5. New Morningstar Analyst Report for Alnylam Pharmaceuticals Inc

    Stock Reports

    Fri, 8 Aug 2014

    Alnylam is in the early stages of building a moat around its RNA-based drug platform.

  6. New Morningstar Analyst Report for Vanda Pharmaceuticals Inc

    Stock Reports

    Thu, 7 Aug 2014

    Given the rarity and limited awareness of non-24 disorder, it will be challenge for Vanda to build the market for the drug.Fanapt's uptake has been limited by its lack of meaningful comparative effectiveness data with other antipsychotics, which may be limiting its market potential.Because of its

  7. New Morningstar Analyst Report for Regeneron Pharmaceuticals Inc

    Stock Reports

    Tue, 5 Aug 2014

    Regeneron’s growing Eylea franchise and full and compelling pipeline underpin its narrow moat.

  8. New Morningstar Analyst Report for Biomarin Pharmaceutical Inc

    Stock Reports

    Tue, 5 Aug 2014

    Accurate diagnosis of rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing scale-up costs.BioMarin's newest Phase III drug candidates could have high hurdles for approval; Pompe disease drug BMN 701 is going

  9. New Morningstar Analyst Report for Amgen Inc

    Stock Reports

    Mon, 4 Aug 2014

    Amgen's progress in cancer and cardiology could stabilize its negative moat trend.

  10. New Morningstar Analyst Report for Exelixis Inc

    Stock Reports

    Fri, 1 Aug 2014

    Phase III results in prostate cancer and melanoma will make 2014 a seminal year for Exelixis.

« Prev12345Next »
Content Partners